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Background & Objective: The increase of pressure in addition to cornea pain and edema could 
result in ischemic optic neuropathy. Different drugs can be employed for cutting down the intraocular 
pressure. The aim of this study was assessment the effect of Apraclonidineversus timololin decreasing 
intra ocular pressure after laser capsulotomy. 
Methods and Materials: This is a double blind clinical trial study that has been done on 200 patients 
with posterior capsular opacity that had been candidate for laser capsulotomy, were evaluated through 
tonometry method. Then the patients were divided randomly into two groups and each group was 
treated by timolol or apraclonidine. Then their intra ocular pressure was recorded 3 and 24 hours after 
the operation. Collected data were analyzed by statistical methods in SPSS.16. 
Results: The mean age of patients in timolol group was 65.7±12.04 yearand in Apraclonidine group 
was 67.8±9.7 year. The mean intra ocular pressure in timolol group was 15±3.8 before, 13.9±4.6 three 
hours, and 12.6±2.6 mmHg 24 hours after the operation. The Mean intra ocular pressure in 
apraclonidine group was 14.7±3.8 before, 14.1±3.3 three hours, and 13.04±2.6 mmHg 24 hours after 
the operation. The effect of apraclonidine in decreasing intra ocular pressure was the same as timolol.  
Conclusion: Apraclonidine can be suggested as the chosen drug with minimal side effects, in patients 
undergone laser posterior capsulotomy.  
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
The posterior capsular opacity, as one of the most common and 
significant side effects of modern cataract surgery, reduces the 
visual function of the patient and the ability of surgeon in 
fundus view (Wormstone, 2002; Bertelmann et al., 2001). 
Laserposterior capsulotomy as an effective and relatively safe 
technique without any requirement of open surgery of the eye 
eliminates the posterior capsular opacity and can be used as a 
standard method (Fankhauser et al., 1982; Syam et al., 2004). 
The side effects of applying such a technique which may entail 
visualdisorder, comprise intra ocular pressure rise, retinal 
detachment,intraocular lens damage, endophethalmitis,iris 
inflammation, cystoids macular edema, cornea edema, vitreous 
and macular edema (Ranta et al., 2000). After laser 
capsulotomy, significant augmentation in the intra ocular 
pressure,has been observed and recorded (Safi et al., 2001; 
Beheshtnejad et al., 2002).The increase of pressurein addition 
to cornea pain and edemacould result in ischemic optic 
neuropathy. This pressure increase might entail other numerous 
side effects, which is likely to lead to several problems and 
hospitalizations. Thus, coming upon a remedy with greater 
efficiency can reduce the intraocular pressure, and is likely to 
decrease these impairments and consumption expenses for  
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solving such problems (Safi et al., 2001). Different drugs such 
as beta blockers (timolol, betaksolol), clonidine, and its 
derivations such as apraclonidine, astazolamid, etc. can be 
employed for cutting down the intraocular pressure 
(Beheshtnejad et al., 2002; Cullom et al., 1993).Currently beta 
blockers, particularly Timolol,are the standard and chosen 
remedy and their potential effect oncontrolling the intraocular 
pressurehas been confirmed (Wormstone, 2002).  
 
Timolol, because of its beta blocking effectand alarge number 
of beta adrenergic receptorsall around thebody organs,could be 
of high side effect;yet for its intraocular pressure decreasing 
power has been selected as a drug for this purpose (Bertelmann 
et al., 2001). Apraclonidine is another drug for this purpose 
which belongs to alpha 2 agonists. Many studies have 
discussed its potentialand beneficial effects on reduction of 
intraocular pressure via affecting alpha 2 adrenergic receptors 
which brings about vasodilation and evacuation of 
anteriorchamber and ultimately intraocular pressure decline 
(Cai et al., 2008).Regarding the high frequency of cataract 
surgery and posterior capsule opacity as its complication which 
usually requires laser capsulotomyon the one hand, and the 
increase of intraocular pressure following laser capsulotomy on 
the other hand, the aim of this study was 
compareApraclonidine versus timolol combination to prevent 
intraocular pressure elevation after laser capsulotomy. 
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METHODS AND MATERIALS 
 
The is adouble blind (nor patient had any information about the 
type of drug, neither did the researcher) clinical trial study that 
has been done on 200 patients. The criterion for taking the 
patients in study was posterior capsule opacity which was 
recognized through clinical examination of eye using Slit 
Lamp after cataract surgery by specialist. The exclusion criteria 
involved being under treatment because of glaucoma, having a 
glaucomasurgery, active intraocular inflammation, anterior 
segment impairments either congenital or resulting from 
surgery.All patientswere informed and written consent 
formwas obtained from them.One hour prior to laser 
capsulotomy, the cases under study were checked for 
intraocular pressure, usingaplanation tonometry.The patients 
were randomly assigned into two groups of treatment and 
comparison and were treated by one of the two regiments of 
timolol.5% (made by Sina Daru Company) or apraclonidine 
0.5% (made by AlkanCompany). The first group was treated 
by timolol and the second one by apraclonidine. All patients 
were followed three and 24 hours after capsulotomy. Collected 
data were analyzed by statistical methods in SPSS.16. 
 
RESULTS  
 
The mean age of patients in timolol and apraclonidine groups 
was 65.68±12.14 and 67.88 ± 9.74, respectively (range: 24-
84).  There was no significant difference between two groups 
regarding their age and gender.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The intraocular pressure was measured in three stages: before 
surgery, 3 hours and 24 hours after posterior laser 
capsulotomy, for the both groups. The results revealed that the 
mean intra ocular pressure in timolol group was 15±3.8, 
13.9±4.6, and 12.6±2.6 mmHg, before capsulotomy, and 3 and 
24 hours after it, respectively. The Mean intra ocular pressure 
in apraclonidine group in the above mentioned intervals was 
14.72±3.75, 14.11±3.3, 13.04±2.57 mmHg, before 
capsulotomy, and 3 and 24 hours after it, respectively, (Table 
1). The decreasing rate of intra ocular pressure in 24 hours 
after posterior laser capsulotomy significantly difference 
between two groups.  (P=0.001) Apraclonidine contrary to 
timolol didn’t lower the intra ocular pressure significantly, 3 
hours after posterior laser capsulotomy. The comparison of two 
drugs with each other revealed no significant difference 
between them (P=0.04), that means both of them acted in a 
similar way in reducing the intra ocular pressure after posterior 
laser capsulotomy (table1). Repeated Measurements revealed 
that the mutual effect of drug and time was not 
significant.Furthermore, the mean difference of pressure 
between two groups was not also meaningful in subsequent 
intervals i.e. the effect of both drugs was similar.  
 
DISCUSSION 
 
In the present study it was observed that, apraclonidine could 
lower the IOP after yag laser capsulotomy in a significant way. 
Its effect was similar to timolol’s effect which is considered as 
a standard drug for preventing from intraocular pressure rise 
following capsulotomy. Beheshtnejad et al. (2002), in a study 
undertaken in Tehran, investigated the effect of timolol0.5 % 
on IOPincrease after posterior laser capsulotomy over 96 cases. 
They came up withthe marked effect of timololand, introduced 
it as a preferred medicine for this purpose (Beheshtnejad et al., 
2002).  
 
However, the current studywas conducted over 200 patients 
suffering from posterior capsule opacity who were candidate 
for undergoing yag laser posterior capsulotomy. Randomly, 
100 eyesreceivedTimolol 0.05%one hour before operation 
(initiation of affecting after 30 min and maximum effecttime 1-
2 hours) and each eye’s IOP  was measured one hour before 
and 3 hours after surgery (the maximum IOP after surgery), 
and 24 hours after operation.It was found that Apraclonidine 
could decrease IOP after yag laser capsulotomy to a significant 
amount. This behavior of apraclonidine is much the same of 
timolol. Celik and et al in a study showed that similar to this 
study, both of eye drops Apraclonidine versus brinzolamide-
timololcombination are effective for prevention and 
Apraclonidine is enough for most of routine cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brinzolamide-timololmay be an option for the eyes those need 
more IOP reduction such as pre-existing glaucoma patients 
who are at higher risk for postoperative IOP elevations. (Celik 
et al., 2016). InastudydesignedbyCai et al, evaluating the 
effective prophylaxisof0.5% timolol maleate for IOP rise 
following YAGlaser capsulotomy, they concluded that pre-
treatment with a topical application of 0.5% timolol is effective 
in preventing IOP elevation after YAG laser capsulotomy. In 
another study comparing the effectiveness brinzolamide and 
apraclonidinefor IOP spikesafter Nd:YAGcapsulotomy,it 
wasreportedthatbothdrugswereeffectiveinpreventingpostlaserI
OP spikes (Cai et al.,2008; Unal et al., 2006). In a prospective, 
randomized, double - masked study, comparing the safety and 
efficacy of FCBT versusdorzolamide 2% +timolol 0. 5%, 
designed by Manni et al, they demonstrated that mean IO 
Preduction with FCB Tranged from 7.2 to9.1 mm Hg, 
representing 28% to 35% reductions from baseline; and they 
concluded that FCBT produced clinically meaning 
fulIOPreductionsfrombaselinethat were non-inferior to those 
seen with dorzolamide 2%+timolol 0.5%, additionally with a 
Table  1. The state of different variables in two groups of study 
 
p-value SD mean Drug variables 
0.04 3.79 14.96 Timolol Pre laser capsulotomy intraocular pressure 
3.75 14.72 Apraclonidine 
0.26 4.63 13.88 Timolol three hours after capsulotomy 
3.3 14.11 Apraclonidine 
0.001 2.55 12.6 Timolol 24 hours after capsulotomy 
2.57 13.04 Apraclonidine 
0.32 28.04 52.03 Timolol Energy(ml jul)  
26.72 55 Apraclonidine 
0.42 12.25 19.38 Timolol Pulse (number) 
10.37 18.71 Apraclonidine  
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better ocularcomfort. (Manni et al., 2009). Cullom et al. 
(1993), in an investigation in England examined the effect of 
apraclonidineon IOP reduction in patients with glaucoma who 
had undergone laser posterior capsulotomy. They discerned 
although apraclonidine could significantly decrease IOP in 
such patients, it didn’t reduce IOP more than other available 
standard drugs (Cullom et al., 1993). Our findingsalso 
confirmed the similar effect of the drug with other standard 
drugs in IOP decrease. Inasmuch as the drugs used in the 
present study were prescribed in a way that the patients 
underwent yag laser capsulotomy in the peak of their effect 
time, i.e. apraclonidine 0.5 %was prescribedone hour prior to 
surgery,(peak of effect 1-2 hours after consumption), and 
timolol 0.5 %one hour prior to surgery (peak of effect 1-2 
hours after consumption). Hereupon it is reasonable to claim 
the statistics and the results of the present study were of more 
validity. In our study, IOP was also measured three hours after 
surgery which is the peak of IOP after laser capsulotomy to 
come up with the results that are more valid and reliable. 
Therefore, it can be claimed that profilactic use of one dose 
apraclonidine 0.5%, 1 hour before surgery is effective and 
lower side effects than the same amount of timolol  0.5% on 
prevention of IOP rise , 1 hour before yag laser capsulotomy. 
(Cullom et al., 1993; Beheshtinejad et al., 2002). 
 
Conclusion 
 
Taking the lower side effects of apraclonidine into account, it 
can be used as an appropriate remedy for reducing the intra 
ocular pressure of patients undergone posteriorlaser 
capsulotomy. However, taking the accessibility and the more 
reasonable price of timolol compared with apraclonidine and 
their similar pressure decreasing effect into account, it seems 
logical to use timololexchangeably with apraclonidine, in the 
case that there is no use prohibition for it.  
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